drugset / Trial / NCT00922714

Scandinavian Intensive Care Unit (ICU) Glutamine Study

NCT00922714

Phase 4 Terminated 1000 enrolled Scandinavian Critical Care Trials Group
RandomizedSingle-groupDouble-blindTreatment

Summary

This is a prospective double-blinded placebo-controlled block randomized study in intensive care patients comparing intravenous glutamine supplementation to placebo. The hypothesis is an improvement of clinical outcome. The primary endpoint is a reduction in the Sequential Organ Failure Assessment (SOFA) score on day 7 of treatment.

Timeline

Start
2003-10
Primary completion
2007-05
Completion
2009-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Glutamine Other / unclassified 0.285 g/kg Intravenous

Indications

No indication recorded.